Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Tae Min Kim's publication output changed over time?
ScholarIQpublication output · 2014–2022
Output grew0% over the shown period — from 1 works in 2014 to 1 in 2022.
1
1
3
1
4
1
1
2014201520162017201920202022
What are the most-cited papers on Tae Min Kim?
ScholarIQmost cited works
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Jürgen Wolf, Takashi Seto, Ji‐Youn Han, Noemı́ Reguart, Edward B. Garon, Harry J.M. Groen, Daniel S.W. Tan, Toyoaki Hida, Maja J.A. de Jonge, Sergey Orlov, Egbert F. Smit, Pierre-Jean Souquet, Johan Vansteenkiste, Maximilian J. Hochmair, Enriqueta Felip, Makoto Nishio, Michael Thomas, Kadoaki Ohashi, Ryo Toyozawa, Tobias R. Overbeck, Filippo de Marinis, Tae Min Kim, Eckart Laack, Anna Robeva, Sylvie Le Mouhaër, Maeve Waldron-Lynch, B. Sankaran, O. Alejandro Balbin, Xiaoming Cui, Monica Giovannini, Mikhail Akimov, Rebecca S. Heist
New England Journal of Medicine. 20201,009 CitationsOPEN ACCESS
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V. Long, Reinhard Dummer, Omid Hamid, Thomas F. Gajewski, Christian Caglevic, Stéphane Dalle, Ana Arance, Matteo S. Carlino, Jean‐Jacques Grob, Tae Min Kim, Lev Demidov, Caroline Robert, James Larkin, James R. Anderson, Janet Maleski, Mark M. Jones, Scott J. Diede, Tara C. Mitchell
The Lancet Oncology. 2019967 Citations
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard, Benjamin Besse, Harry J.M. Groen, Pierre-Jean Souquet, Élisabeth Quoix, Christina S. Baik, Fabrice Barlési, Tae Min Kim, Julien Mazières, Silvia Novello, James R. Rigas, Allison Upalawanna, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson
The Lancet Oncology. 2016883 CitationsOPEN ACCESS
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan, Jamie Hirata, Elicia Penuel, Joseph N. Paulson, Ji Cheng, Grace Ku, Matthew J. Matasar
Journal of Clinical Oncology. 2019780 CitationsOPEN ACCESS
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok, Makoto Nishio, Giorgio V. Scagliotti, David R. Spigel, Stéphanie Deudon, Cheng Zheng, Serafino Pantano, Patrick Urban, Cristian Massacesi, Kalyanee Viraswami-Appanna, Enriqueta Felip
The Lancet Oncology. 2017582 CitationsOPEN ACCESS
Related on ScholarIQ
New Generation University College
Institution
Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer
Paper
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Paper
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
Paper
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Paper
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Paper